IART (Integra Lifesciences Holdings) 6-Month Price Index: 1.37 (As of Aug. 24, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IART Integra Lifesciences Holdings Corp IART
70 GF Score
Price $16.59
GF Value $20.52
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is Integra Lifesciences Holdings 6-Month Price Index?

Integra Lifesciences Holdings IART -0.96% 70 6-Month Price Index is 1.37 as of Aug. 24, 2026. GuruFocus rates IART with a GF Score™ of 70/100 and a GF Value™ of $20.52 (Modestly Undervalued). The stock has 8 warning signs investors should review.

6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. It’s calculated by current share price divided by share price 6-months ago. As of today (2026-08-24), Integra Lifesciences Holdings's 6-Month Price Index is 1.37.

Integra Lifesciences Holdings  (NAS:IART) 6-Month Price Index Explanation

Price Index (PI) also called momentum. Strategies involving Price Index are also known as momentum strategies as they allow investors to profit from a company’s stock price. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago.

The investment strategy for momentum investors is to buy winners and sell losers. That is, buy stocks that performed well and sell stocks that performed poorly in the past.

Integra Lifesciences Holdings 6-Month Price Index Related Terms

IART vs ENOV, AHCO, INSP: 6-Month Price Index Comparison

For the Medical Devices subindustry, Integra Lifesciences Holdings's 6-Month Price Index, along with its competitors' market caps and 6-Month Price Index data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IART
70GF Score
Integra Lifesciences Holdings Corp IART
6-Month Price Index is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Integra Lifesciences Holdings  (NAS:IART) 6-Month Price Index Calculation

6-Month Price Index is calculated as following:

6-Month Price Index=Current Share Price / Share Price 6-Months Ago

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 6-Month Price Index →
What does a 6-Month Price Index of 1.37 mean?
Integra Lifesciences Holdings (IART) has a 6-Month Price Index of 1.37 as of Aug. 24, 2026. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Integra Lifesciences Holdings and its competitors.
Is Integra Lifesciences Holdings' 6-Month Price Index too high?
Integra Lifesciences Holdings' current 6-Month Price Index is 1.37. Overall, Integra Lifesciences Holdings has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Integra Lifesciences Holdings' 6-Month Price Index compare to ENOV and AHCO?
Integra Lifesciences Holdings' 6-Month Price Index of 1.37 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-Month Price Index for a Medical Devices & Instruments company?
A good 6-Month Price Index depends on the Medical Devices & Instruments industry context. However, 6-Month Price Index should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-Month Price Index mean?
A high 6-Month Price Index can signal that a stock is expensive relative to its fundamentals. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Integra Lifesciences Holdings and its competitors. Integra Lifesciences Holdings's current 6-Month Price Index is 1.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integra Lifesciences Holdings stock overvalued right now?
Based on GuruFocus' analysis, Integra Lifesciences Holdings (IART) is currently considered Modestly Undervalued. The stock's GF Value™ is $20.52, compared to a current price of $16.59 — trading 19.2% below its estimated fair value. The current 6-Month Price Index is 1.37. Integra Lifesciences Holdings' overall GF Score™ is 70/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-Month Price Index calculated?
6-Month Price Index is calculated from a company's financial statements. For Integra Lifesciences Holdings (IART), the current 6-Month Price Index is 1.37 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Integra Lifesciences Holdings (IART) Overvalued in 2026?

Based on GuruFocus' analysis, Integra Lifesciences Holdings stock appears to be undervalued. The current stock price of $16.59 is trading 19.2% below its estimated GF Value™ of $20.52. GuruFocus considers Integra Lifesciences Holdings to be Modestly Undervalued.

Key valuation signals for IART:

  • 6-Month Price Index: 1.37
  • GF Value™: $20.52 vs. price of $16.59 (19.2% below fair value)
  • GF Score™: 70/100 with 8 warning signs

No single metric tells the full story. See the IART stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Integra Lifesciences Holdings Business Description

Other Exchanges IL3:Germany
Address 1100 Campus Road, Princeton, NJ, USA, 08540
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.
70GF Score

Get the complete analysis for IART

6-Month Price Index is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.59
Price
$20.52
GF Value